The NGF System and its interplay with endocannabinoid signalling, from peripheral sensory terminals to the brain: new targets for the development of next generation drugs for neuropathic pain

On June 23 to 26 2018, the Paincage partner Juan Carlos Arevalo (USAL) organized in Salamanca the international conference on Neurotrophic Factors, the international NGF meetings held every two years. This is the most important meeting worldwide on NGF and neurotrophins, a forum that periodically calls together the most eminent scholars and scientist in the field. In the meeting (, two out of nine sessions were dedicated to “Pain, Neurotrophic Factors and Therapies”, and different members of the Paincage consortium were invited speakers and presented their work to the wider community (  Silva Lisa (from Juan Carlos Arevalo lab at USAL), Anders Nikjaer (AU), Antonino Cattaneo (SNS), Simona Capsoni (SNS). Patrick Ernfors from Karolinska Institute in Stockholm reported results performed in collaboration with Tibor Harkany (MUW). In the meeting Mark Brown, the Clinical Leader of the Tanezumab anti NGF program at Pfizer, reported on the progress of anti NGF clinical trials, after the clinical holds by FDA. This meeting was a very good occasion to present some of the Paincage results to the most relevant scientific community.

LINK to the Web page of the meeting:

Leave a reply

You must be logged in to post a comment.